

1 **Title Page**

2

3 **Full title:** A Randomized Clinical Trial Comparing Visual Inspection with Acetic Acid (VIA) to
4 Pocket Colposcopy for the Triage of HPV+ women living with HIV in Kisumu, Kenya (162
5 characters)

6 **Short Title:** RCT Comparing Diagnostic Performance for cervical cancer screening (66
7 characters)

8 **Author information:** Mary E. Dotson (1,2); Eliza Steinberg (1,2); Maria Olivia Santos (1,2);
9 Jeniffer Ambaka, (5); Megan Huchko MD MPH (3,4); Nimmi Ramanujam PhD (1,2)

10 1. Center for Global Women’s Health Technologies, Duke University, Durham NC, USA

11 2. Biomedical Engineering Department, Duke University, Durham NC, USA

12 3. Duke Global Health Institute, Duke University, Durham NC, USA

13 4. Center for Global Reproductive Health, Duke University, Durham NC, USA

14 5. Kenya medical Research Institute, Kisumu, Kenya

15 **Corresponding Author:** Dr. Nimmi Ramanujam, nimmi.ramanujam@duke.edu

16 **Disclaimers:** The research conducted and described in this article are the original work of the
17 authors.

18 **Financial Disclosure:** This RCT (NCT04998318) was supported by USAID-Development
19 Innovation Ventures (DIV) under award #7200AA19FA00001

20 **Clinical Trails Number:** NCT04998318

21 **Key words:** cervical cancer screening; HPV-based screening, women living with HIV, digital
22 health and Kenya

23 **Competing Interests Statement:** Dr. Nimmi Ramanujam is an advisor and Mary E Dotson is an
24 employee of the Calla Health Foundation which have commercialized the Pocket Colposcope for
25 distribution globally.

26 **Corresponding Author:** Nimmi Ramanujam PhD, +1-919-475-8358; 140 Science Drive Durham
27 NC 27708

28 **Author Contribution:** NR and MH conceived the study design. All authors (MD, ES, MS, MH,
29 NR) aided in the data collection, data analysis, writing and final review before submission.

30 **Creative Commons License:** All authors agree to publish this article under the creative Commons
31 Attribution 3.0 IGO license.

32

33 **Abstract**

34 **Objective:** The World Health Organization recommends a “screen, triage, treat” approach for
35 cervical cancer screening for Women Living with HIV (WLWH) in resource-limited settings, with
36 Human Papillomavirus (HPV) testing preferred for screening. We assessed the use of the Pocket
37 colposcope as an adjunct tool to Visual Assessment with Acetic Acid (VIA) for the triage of HPV+
38 WLWH.

39 **Methods:** We carried out a randomized clinical trial across six clinics in Kisumu, Kenya between
40 November 2022 and April 2023 (NCT04998318). WLWH who screened positive with self-
41 collected HPV were randomized to either the VIA or Pocket arm. Exam positivity was determined
42 by presence or absence of aceto-white epithelium (AWE). Directed biopsies were performed on
43 AWE; if negative, two random biopsies were taken. Pathology was used to determine diagnostic
44 accuracy. Providers and participants took brief surveys after each exam.

45 **Findings:** The rate of a positive exams was 17.3% for VIA compared to 14.3% for the Pocket. The
46 overall rate of CIN2/3 was 15.4%, with 12.2% in the VIA Arm and is 18.8% in the Pocket Arm.
47 Pocket and VIA performed comparably on all sensitivity, specificity and negative predictive value
48 (NPV). For Pocket compared to VIA, Sensitivity was 26.3% vs 25.0%; specificity was 88.9% vs
49 84.0%; and NPV was 82.9% vs 87.1%. However, the positive predictive value (PPV) of the Pocket
50 colposcope arm was almost a factor of two higher than that of the VIA arm (Pocket arm PPV was

51 375 is and that of the VIA arm was 20.6%). The Pocket Colposcope was acceptable to providers
52 and patients for clinic-based triage of HPV positivity.

53 **Conclusion:** Provider assessment with the Pocket colposcope detected significantly more treatable
54 disease, thereby reducing the need for overtreatment. This study indicates that the Pocket
55 colposcope is a feasible, lower cost colposcopic device, which could facilitate biopsy-confirmation
56 of disease, increase provider training, patient education and facilitate remote diagnosis.

57 **Introduction**

58 Cervical cancer remains a global health challenge because effective prevention
59 technologies are not accessible to most women around the world. Each year, almost 600,000
60 women worldwide are diagnosed with cervical cancer, and over 330,000 women die from the
61 disease.(1) Invasive cervical cancer is highly preventable through vaccination for the human
62 papillomavirus (HPV) or screening, diagnosis, and treatment of cervical precursor lesions.(2) The
63 highly effective prevention methods that are the standard in most developed countries are not
64 widely available in low- and middle-income countries (LMICs) due to cost and infrastructure
65 requirements. To avert deaths of up to 50 million women who will not have effective coverage
66 from the vaccine in the next fifty years, the World Health Organization (WHO) recommends
67 adoption of simplified screening technologies coupled directly with treatment.(3) One such
68 strategy, molecular testing for HPV, has been shown to reduce the incidence and mortality from
69 cervical cancer when coupled directly with outpatient ablative treatment for women with HPV-
70 positive results.(4) However, this “screen & treat” approach leads to overtreatment with
71 consequent burdens on both women and health care systems, and potential under-treatment of
72 missed cancers.(5) These risks are increased among women living with HIV (WLWH), and as a
73 result, the WHO recently updated their recommendations to include a triage step for this

74 population.(6) Kenya, a middle-income country with a high burden of cervical cancer and HIV,
75 has also adopted guidelines that recommend HPV with a triage step prior to treatment.(7)

76 The currently recommended triage tests, colposcopy or visual inspection with acetic acid
77 (VIA), are not effective solutions for HPV positive women in LMICs. Colposcopy with biopsy is
78 the standard of care for positive screening tests in most high-income settings. Colposcopes are
79 expensive and require a second visit to a referral facility, a trained provider, a pathologist, and a
80 concurrent tracking system for patients, specimens and results. All these factors make colposcopy
81 and biopsy an unrealistic triage method for many women in LMICs. VIA, a simpler and less
82 expensive test, is often used instead. VIA involves applying acetic acid to the cervix, examining
83 the cervix with the naked eye, followed by a diagnosis and treatment decision. VIA has high
84 variability depending on provider experience, patient age, and size of lesion and has low sensitivity
85 due to lack of adequate lighting and magnification.²⁻⁷ Because there is no ability to capture images
86 with VIA, there is no mechanism for quality monitoring or opportunity for skills improvement.(8)
87 (9) There remains a crucial need for a triage technique that is low-cost, easy-to-use and will
88 accurately identify precancerous lesions.

89 To address these gaps, our team developed a low-cost, mobile colposcope, called a Pocket
90 Colposcope.(10)(11) The device is powered by a cell phone which houses a software called the
91 Calla Health App (CHA) through which patient information and corresponding images can be
92 captured, stored, and transferred between health facilities or to remote specialists for diagnostic
93 evaluation. The Pocket is inserted through a speculum and positioned at a short working distance
94 (3 cm) to the cervix, obviating the need for high-end optics and high-resolution cameras used in
95 long working distance (30 cm) standard Colposcopes. The Pocket Colposcope has image quality

96 comparable with standard colposcopes and has the capability to perform both white light imaging
97 of acetic acid and green light imaging.(12)

98 The Pocket colposcope has been tested in more than 6 countries (most of which are
99 LMICs), and has been successfully used by physicians, nurses, and clinical officers. The Pocket
100 colposcope can be used to bridge the gaps in health care infrastructure and services. Specifically,
101 it can be used by primary providers as an adjunct to improve visual triage for women who are HPV
102 positive or can be coupled with biopsy and used as a lower cost replacement to colposcopy. The
103 CHA software can provide linkages between providers and care facilities, facilitating remote
104 diagnosis and reducing attrition to completion of care. Further, the images can be stored in a
105 database that can be retrieved for training of deep learning algorithms which can be used to
106 facilitate diagnosis either as a standalone tool or as an aid to a physical provider.

107 We sought to evaluate the effectiveness of the Pocket as an adjunct to visual inspection
108 through a randomized comparison of diagnostic accuracy of standard VIA to that of the Pocket
109 colposcope for the triage of HPV positive WLWH in Western Kenya (Figure 1). To evaluate
110 implementation readiness, we compared provider and patient experiences with the VIA and
111 Pocket. **Figure 1.** Pocket Colposcope and Calla Health App Integration.

112 **Methods**

113 *Study Site*

114 This study took place in 6 clinics providing HIV care in the Municipality of Kisumu, Kenya
115 from November 2022 to June 2023. Kisumu is in the Nyanza Province in western Kenya,
116 consisting of a population approximately 500,000 people. It contains both rural and urban
117 households.

118 *Study Design*

119 We carried out an RCT to examine the diagnostic accuracy of the Pocket Colposcope as a
120 triage tool for cervical cancer screening. WLWH were approached across six clinics to participate
121 in HPV testing using self-collected cervical sampling. Upon receiving a positive HPV test result,
122 women were recruited to the study if they were between 25 and 65 years of age and planned to
123 undergo evaluation for treatment at the clinic following their positive HPV test result. Women
124 were excluded if they declined to consent to the study, were pregnant, had a history of cervical
125 cancer, or had a pelvic exam with concern for infection or invasive cervical cancer.

126 Women who consented to the study were randomized to either the standard-of-care (VIA)
127 arm or the intervention (Pocket Colposcope) arm. For women in both study arms, providers applied
128 acetic acid to the cervix and waited 60 seconds before visualizing the cervix for any aceto-whitened
129 lesions. For women randomized to the standard-of-care arm, providers performed standard VIA.
130 In the Pocket arm, providers used the Pocket Colposcope to visualize the cervix before and after
131 acetic acid application and to capture images using both white and green light (Figure 2). **Figure**
132 **2.** Enrollment of 404 HPV+ women living with HIV, were randomized to receive the control arm
133 (VIA) or the intervention arm (enhanced VIA using the Pocket Colposcope). An imbalance in
134 participant numbers in each arm occurred due to a technical error in the randomization scheme.

135 In both arms, providers provided a diagnosis of either “positive” if they believed there was
136 an area of aceto-white epithelium (AWE) present after a minute or “negative” if no changes were
137 seen. Women in both arms had biopsies taken in areas with AWE, or if no AWE was visualized,
138 providers took biopsies at two random locations. Per WHO recommendations all HPV screen-
139 positive women eligible for ablative treatment received treatment in the clinic, regardless of the
140 provider’s visual diagnosis.⁽⁷⁾ Participants who were suspected to have lesions too large to treat

141 (using VIA or Pocket), or areas with suspected invasive carcinoma were referred for treatment at
142 an advanced care center. They were withdrawn from enrollment.

143 Following the exam, a member of the research team administered a questionnaire to assess
144 the participant's experiences with VIA or the Pocket Colposcope, knowledge of cervical cancer
145 before and after the exam, comfort, and pain during the exam, perceived confidence in the
146 provider's diagnosis, and the likelihood of recommending the exam to a friend. Providers filled
147 out surveys after each exam to assess their experiences with VIA or the Pocket Colposcope as it
148 related to their ability to complete the exam, ability to make a diagnosis, perception of patient
149 comfort, experience with patients sharing any discomfort, concerns, or pain during the exam, with
150 opportunity for qualitative elaboration, and experience with any challenges during the exam.

151 *Provider and Study Staff Training*

152 Kenyan providers were trained on using the Pocket Colposcope and CHA using the “train
153 the trainer” method. A clinical officer with 5 years of training and experience performing VIA
154 partnered with staff from Duke University to provide clinical and device training to the KEMRI
155 research assistants, nurses, and community health volunteers prior to the start of enrollment. The
156 training covered basic HPV and Cervical cancer background best practices for VIA, the Pocket
157 Colposcope (capturing high-quality images with the Pocket Colposcope) and CHA in clinical
158 exams and optimizing clinic workflow. Following the in-person training, KEMRI study staff
159 trained local providers on operating the Pocket Colposcope and the accompanying CHA app.
160 Providers were clinical officers and nurses providing general outpatient and HIV-specific care in
161 government of Kenya clinics. Study providers incorporated study visits into their regular clinical
162 duties. Duke study staff maintained weekly calls with KEMRI research assistants throughout the
163 course of the study to troubleshoot any issues.

164 *Data Management and Analysis*

165 All exam forms, participant and provider surveys, and cervix images were documented and
166 saved in CHA on a mobile device and were later uploaded to a HIPAA-compliant online database.
167 Histopathological results from cervical biopsies were later matched to each corresponding
168 participant identification number. Data were analyzed using R (version 2022.07.02) to determine
169 the concordance between provider diagnoses and histopathology. Histopathological results were
170 used as the “gold standard” when calculating, sensitivity, specificity, positive predictive value
171 (PPV), and negative predictive value (NPV) for provider diagnoses in each study arm. For
172 participant and provider surveys, frequencies and percentages are presented for each answer
173 choice.

174 *Ethical Review*

175 The study protocols, consent forms, and provider and patient questionnaires were reviewed
176 by the institutional review boards of both the Kenya Medical Research Institute (KEMRI) and
177 Duke University prior to study initiation.

178 **Results**

179 *Demographics*

180 Between November 2022 and April 2023, 2,794 women living with HIV screened for HPV,
181 503 (18%) tested HPV-positive, and 404 HPV-positive women were enrolled, randomized, and
182 underwent triage with VIA (208) or the Pocket colposcope (196), which will be referred to the
183 Pocket from this point on (Figure 2). The median age of the participants was 39 years old (IQR:
184 28-65). The largest number of patients were enrolled at Lumumba, a sub-county hospital with the
185 greatest patient volume among the six clinics (Table 1). Majority of women had three or more
186 children, approximately 50% of women had previously been screened for cervical cancer, and

187 approximately 60% used a contraceptive, most commonly an injectable or implant. **Table 1.**
188 Demographic and clinical characteristics of HPV+ Women Living with HIV assigned to Pocket or
189 VIA study arm.

190
191 *Patient Diagnosis (Provider Visual Diagnosis and Histopathology)*

192 In the Pocket arm, providers used the Pocket Colposcope to visualize the cervix before and
193 after acetic acid application and to capture images using both white and green light (Figure 2).
194 Only white light images were used to confer a diagnosis. The pre-acetic acid images as well as the
195 green light images were captured for the purposes of algorithm development. It should be noted
196 that at the time of data analysis, 388 out of 404 enrolled patients had processed biopsy results. The
197 remaining 16 were lost during processing, resulting in a sample size of 196 and 197 for the Pocket
198 arm and the VIA arm, respectively. The sample size in Tables 3,4, and 5 are consistent with that
199 in Table 2. The percentage of a positive visual exam was 17.3% (95% CI = 12.4-23.1%) for the
200 VIA arm compared to 14.3% (95% CI = 9.7-20.0%) for the Pocket arm ($X^2 = 0.48$, $p = 0.487$;
201 Figure 3). The overall rate of CIN2/3 confirmed on pathology was 15.5%, with 24 cases (12.2%)
202 in the VIA arm and 36 cases (18.8%) in the Pocket Arm. There was a high rate of CIN3 for both
203 the Pocket and VIA arms (17.3% and 9.6%, respectively) (Figure 3; Table 2). Majority of biopsies
204 were histologically diagnosed as negative (NILM) in both the Pocket and VIA arms (75.9% and
205 80.2%, respectively). **Figure 3.** Representative cervix images of HPV+ women living with HIV,
206 imaged with Pocket Colposcope at each stage of cervical precancer (pathology confirmed). **Table**
207 **2.** Provider and histopathology diagnoses following exams with Pocket Colposcope or VIA.

208 The diagnostic characteristics were similar for VIA and Pocket with exception of the PPV.
209 The sensitivity for correctly identifying CIN2+ (including CIN2, CIN3, SCC, and AGC) lesions
210 was similar (26.3% vs. 25.0%, respectively; Table 3). The specificity of the Pocket arm was 4.9%

211 higher than that of the VIA arm (88.9% vs. 84%, respectively; Table 3). The NPV for the VIA arm
212 (87.1%) was approximately 4% higher than that of the Pocket arm (82.9%). On the other hand, the
213 PPV for the Pocket arm (37%) was almost a factor of two higher than that of the VIA arm (20.6%).
214 **Table 3.** Sensitivity, specificity, positive predictive value (PPV), and negative predictive value
215 (NPV) for provider visual diagnosis of the cervix, compared to pathology.

216 *Provider and Participant Experience with Pocket Colposcope Compared to VIA*

217 Study exams were carried out by 14 providers (Table 4). Each provider completed both
218 Pocket and VIA exams based on which arm the patient was randomized to following consent.
219 Majority of providers expressed “no challenges” during the exam for both procedures (96.0% and
220 97.1% for Pocket and VIA, respectively; Table 4). When using the Pocket, less than 1% of
221 providers expressed difficulty with the internet, recording patient information/results, or perceived
222 patient discomfort during a Pocket examination. Difficulty visualizing the patient’s cervix was
223 expressed for 2.5% of Pocket exams compared to 0.5% of VIA exams. Additionally, providers
224 answered that they were able to “complete the exam” and “make a diagnosis” for both the Pocket
225 and VIA exams 100% of the time (Table 4).

226 A total of 190 women in the Pocket arm and 197 participants in the VIA arm completed
227 the participant survey (Table 5). Almost all participants stated that the provider explained the
228 importance of getting treated for cervical cancer and why they were either being examined by VIA
229 or the Pocket (Table 5). Participants indicated little or no knowledge about cervical cancer and
230 cervical cancer prevention prior to the exam, with majority expressing “none” or a “little”
231 knowledge prior to the exam (Pocket: 94.8%, VIA: 95.9%). However, participants felt that their
232 knowledge increased following the exam, with 81.0% of participants in the Pocket arm and 84.8%

233 of participants in the VIA arm stating that they knew “somewhat” or “very much” about cervical
234 cancer and its prevention.

235 Providers answered that their patients shared their discomfort, concern, or pain during the
236 examination with both the Pocket and VIA alone (27.7% and 26.9% respectively; Table 4).
237 Consistently, majority of participants expressed little or no pain (Pocket: 93.2%, VIA: 92.8%;
238 Table 5). Almost all participants in both arms stated that they were “somewhat” or “very much”
239 confident about the providers’ assessment (Pocket: 96.8%, VIA: 97.4%) and similarly, most would
240 “likely” or “very likely” recommend the exam to a friend (Pocket: 98.9%, VIA: 99.5%). **Table 4:**
241 Post-exam Provider Pocket vs VIA Survey Question 8 and 10, full survey in Appendix. **Table 5.**
242 Post-exam Female Participant Pocket vs. VIA Survey Responses, full survey in Appendix.

243 **Discussion**

244 We sought to compare the diagnostic accuracy of VIA to the Pocket colposcope through an
245 RCT of HPV positive women living with HIV (WLWH) in western Kenya. The results of this
246 study show prevalence of CIN lesions among HIV-positive women consistent with other
247 studies.(13)(14) The study arm that used the Pocket colposcope had similar sensitivity, and a
248 slightly lower specificity and NPV compared to that of VIA; however, it had almost a factor of
249 two higher PPV. In this scenario, the Pocket Colposcope aided providers in yielding a greater
250 percentage of pathology-confirmed positive visual diagnoses compared to VIA, without
251 sacrificing sensitivity, thus avoiding unnecessary treatment. Providers expressed satisfaction with
252 the use of the Pocket colposcope and reported very few challenges with the additional technology
253 such as internet access and documenting information/results of the exam on the CHA app.

254 Majority of participants were satisfied with the exams in both arms, including with their
255 provider’s explanation of the procedures and in the provider’s assessment, and would recommend

256 the exam to a friend. They also expressed that their knowledge about cervical cancer screening
257 and prevention increased after the exam. While very few participants reported pain during the
258 survey, it is not surprising that a large percentage of women expressed some pain or discomfort
259 during the exam, with no difference between arms. There are a number of studies that report that
260 women fear the speculum-based exam and find that the speculum is painful and a deterrent for
261 follow-up care.(15)(16)(17) The Pocket did not seem to add any additional discomfort or pain to
262 the speculum exam.

263 VIA has been promoted as an effective strategy in low-resource settings because it is
264 resource efficient and providers with limited colposcopy experience can be trained to complete the
265 exam. One study in Kenya of WLWH showed that VIA had a sensitivity of 69.6% and specificity
266 of 51% when CIN2+ lesions were used as the threshold.(14) Another study among WLWH in
267 Kenya demonstrated VIA to have a sensitivity, specificity, PPV, and NPV of 86.6%, 71.6%, 30.3%
268 and 97.4%, respectively for CIN2+ lesions as the threshold(18) Finally, one study conducted
269 among WLWH in Nigeria reported a sensitivity, specificity, and PPV of VIA to be 76%, 83%, and
270 34% respectively for CIN2+ lesions as the threshold. The specificity of VIA in our study (84.0%)
271 was comparable to or in some cases better than what has been reported previously; however,
272 sensitivity (25.0%) was substantially lower. This is likely because none of these studies included
273 HPV screening. On the other hand, the PPV (20.6%) and NPV (87.1%) in our study were more
274 comparable with that reported previously.(19)

275 It is important to highlight that in general, direct comparison between different studies and
276 ours is difficult owing to different populations, study designs, device characteristics, and provider
277 training. Therefore, comparison between different approaches within the same study can
278 potentially reduce these inconsistencies. Several investigators have compared VIA based on the

279 unaided eye and imaging, as we have reported in this study. It is important to note that none of
280 these studies were carried out on a HIV+ population. Comparison between VIA and the
281 Cervioscope without HPV screening (a 13.6 MP Sony cyber shot camera) resulted in a sensitivity,
282 specificity, PPV and NPV of 71.42%, 92%, 20%, and 99.1%, for VIA and 71.42%, 93.62%,
283 23.8%, and 99.1% for Cervioscope, when compared to histopathology.(20) Another study that
284 compared VIA to digital colposcopy had different findings. The sensitivity, specificity, PPV, and
285 NPV were 62.5%, 98.8%, 90.9%, and 93.2% for VIA and 46.7%, 97.6%, 77.8%, 91%, for digital
286 colposcopy, and similar to the case in the previous study, no HPV test was performed as a primary
287 screening step.(21) Surprisingly, both sensitivity and specificity were lower for the imaging arm.
288 In another study, one gynecologist in Madagascar was asked to complete VIA for HPV+ women
289 and then smartphone images were sent to 3 expert colposcopists in Geneva for classification.
290 Interestingly, the comparison of groups did not reach significance due to small sample size, but
291 the results were suggestive of the potential of digital colposcopy.(22) It is expected that any two-
292 step screening process, such as HPV followed by VIA or Pocket, will have a lower sensitivity than
293 a single step process since we are able to more effectively reduce false positives.

294 The results from our RCT study showed consistently lower sensitivity of 25-30% in both the
295 VIA and Pocket colposcope arms. Much of this decrement in sensitivity is the fact that the visual
296 exams were performed as a triage step after an initial HPV test, compared to the cited studies in
297 which the visual assessment was the primary screening exam. However, this study has provided
298 much information about the need for improved provider training and continued feedback and
299 mentorship on exam and diagnostic quality. Because we sought to test the Pocket in a real-world
300 clinical setting in Kenya, we engaged providers with varying levels of colposcopic expertise and
301 experienced a high rate of provider turnover unrelated to the study. This is further supported by

302 the fact that in our group’s previous studies, in which we found similar sensitivities and
303 specificities between expert interpretation (by the same providers) of the Pocket colposcope and
304 standard-of-care colposcope images (sensitivity and specificity was 79.8% and 56.6%,
305 respectively for the standard of care colposcope and 71.2% and 57.5%, respectively for Pocket
306 colposcope images).(12)

307 Ultimately, our study and those reported by others point to the importance of standardizing
308 diagnostic interpretation, and there is a concerted effort in augmenting visual interpretation with
309 machine learning algorithms. However, the ability to capture non-blurry images of all four
310 quadrants of the cervix with minimal glare is equally important as any algorithm will be influenced
311 by these factors.(23) A different study analyzing a portion of the data set used in the present study
312 used an automated blur detection algorithm to assign binary categories of “Blurry” or “Clear” to
313 each Pocket image.(24) This study found that an expert provider’s confidence in identifying a
314 lesion was significantly higher in “Clear” versus “Blurry” images.(25) Another study assessing an
315 automated diagnostic algorithm for cervix images taken with a mobile phone camera found that
316 de-blurring images improved algorithm performance by 21.4%.(26) In addition to blur, other
317 confounding factors, such as glare, can impact diagnostic interpretation. Robust, standardized, and
318 continuous training on image interpretation and image quality will continue to be an important
319 factor in the hands of less experienced providers. Automated methods/algorithms that provide real
320 time or near real time feedback on the quality of the image during the exam can allow the provider
321 to retake images, potentially improving quality control.

322 Overall, we found the Pocket Colposcope to be acceptable to providers and patients for
323 clinic-based triage of HPV positivity in western Kenya. We did not find that Pocket colposcope
324 substantially increased specificity or sensitivity over VIA when used as a visual adjunct alone

325 though PPV was significantly higher reducing overtreatment. However, this study does provide
326 key data to support use of Pocket as a feasible, lower cost colposcopic device, which could
327 facilitate biopsy-confirmation of disease. The Pocket can also be explored as a mode of increased
328 provider training, patient education or a way to facilitate remote diagnosis. Finally, the images and
329 image quality feedback can be used to inform algorithms for image improvement or automated
330 algorithms for diagnosis of precancer.

331

332 **Acknowledgments:** The team would like to acknowledge the significant efforts of the Kenya
333 Medical Research Institute (KEMRI). Jeniffer Ambaka, study coordinator, Saduma Ibrahim, Data
334 Manager, Evans Obuto and the research assistants.

335

336

337 **References**

- 338 1. J F, I S, M E, R D, S E, C M, et al. GLOBOCAN 2012: Estimated Cancer Incidence,
339 Mortality and Prevalence Worldwide in 2012 v1.0 [Internet]. [cited 2024 Jun 11]. Available
340 from: [https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-](https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012)
341 [Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012](https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012)
- 342 2. Comprehensive cervical cancer control. A guide to essential practice - Second edition
343 [Internet]. [cited 2024 Jun 11]. Available from: [https://www.who.int/publications-detail-](https://www.who.int/publications-detail-redirect/9789241548953)
344 [redirect/9789241548953](https://www.who.int/publications-detail-redirect/9789241548953)
- 345 3. Comprehensive cervical cancer prevention and control - a healthier future for girls and
346 women [Internet]. [cited 2024 Jun 11]. Available from: [https://www.who.int/publications-](https://www.who.int/publications-detail-redirect/9789241505147)
347 [detail-redirect/9789241505147](https://www.who.int/publications-detail-redirect/9789241505147)
- 348 4. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV
349 screening for cervical cancer in rural India. *N Engl J Med*. 2009 Apr 2;360(14):1385–94.
- 350 5. Shastri SS, Temin S, Almonte M, Basu P, Campos NG, Gravitt PE, et al. Secondary
351 Prevention of Cervical Cancer: ASCO Resource-Stratified Guideline Update. *JCO Glob*
352 *Oncol*. 2022 Sep;8:e2200217.
- 353 6. New evidence on cervical cancer screening and treatment for women living with HIV
354 [Internet]. [cited 2024 Jun 12]. Available from: [https://www.who.int/news/item/12-12-2023-](https://www.who.int/news/item/12-12-2023-new-evidence-on-cervical-cancer-screening-and-treatment-for-women-with-hiv)
355 [new-evidence-on-cervical-cancer-screening-and-treatment-for-women-with-hiv](https://www.who.int/news/item/12-12-2023-new-evidence-on-cervical-cancer-screening-and-treatment-for-women-with-hiv)
- 356 7. Viviano M, DeBeaudrap P, Tebeu PM, Fouogue JT, Vassilakos P, Petignat P. A review of
357 screening strategies for cervical cancer in human immunodeficiency virus-positive women in
358 sub-Saharan Africa. *Int J Womens Health*. 2017 Feb 2;9:69–79.
- 359 8. Vedantham H, Silver MI, Kalpana B, Rekha C, Karuna BP, Vidyadhari K, et al.
360 Determinants of VIA (Visual Inspection of the Cervix After Acetic Acid Application)
361 positivity in cervical cancer screening of women in a peri-urban area in Andhra Pradesh,
362 India. *Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc*
363 *Prev Oncol*. 2010 May;19(5):1373–80.
- 364 9. Lohiya A, Daniel RA, Kumar D, Varghese C, Rath RS, Abdulkader RS, et al. Effectiveness
365 of Visual Inspection with Acetic Acid (VIA) Screening on Cervical Cancer Mortality and
366 Incidence - A Systematic Review and Meta-Analysis. *Asian Pac J Cancer Prev APJCP*. 2022
367 Feb;23(2):399–407.
- 368 10. Lam CT, Krieger MS, Gallagher JE, Asma B, Muasher LC, Schmitt JW, et al. Design of a
369 Novel Low Cost Point of Care Tampon (POCkeT) Colposcope for Use in Resource Limited
370 Settings. *PloS One*. 2015;10(9):e0135869.

- 371 11. Lam CT, Mueller J, Asma B, Asiedu M, Krieger MS, Chitalia R, et al. An integrated strategy
372 for improving contrast, durability, and portability of a Pocket Colposcope for cervical cancer
373 screening and diagnosis. *PLOS ONE*. 2018 Feb 9;13(2):e0192530.
- 374 12. Mueller JL, Lam CT, Dahl D, Asiedu MN, Krieger MS, Bellido-Fuentes Y, et al. Portable
375 Pocket colposcopy performs comparably to standard-of-care clinical colposcopy using acetic
376 acid and Lugol's iodine as contrast mediators – An investigational study in Perú. *BJOG Int J
377 Obstet Gynaecol*. 2018 Sep;125(10):1321–9.
- 378 13. Sankaranarayanan R, Wesley R, Somanathan T, Dhakad N, Shyamalakumary B, Amma NS,
379 et al. Visual inspection of the uterine cervix after the application of acetic acid in the
380 detection of cervical carcinoma and its precursors. *Cancer*. 1998 Nov 15;83(10):2150–6.
- 381 14. Mabeya H, Khozaim K, Liu T, Orango O, Chumba D, Pisharodi L, et al. Comparison of
382 Conventional Cervical Cytology Versus Visual Inspection With Acetic Acid Among Human
383 Immunodeficiency Virus–Infected Women in Western Kenya. *J Low Genit Tract Dis*. 2012
384 Apr;16(2):92.
- 385 15. Rosser JI, Hamisi S, Njoroge B, Huchko MJ. Barriers to Cervical Cancer Screening in Rural
386 Kenya: Perspectives from a Provider Survey. *J Community Health*. 2015 Aug;40(4):756–61.
- 387 16. Nwankwo KC, Aniebue UU, Aguwa EN, Anarado AN, Agunwah E. Knowledge attitudes
388 and practices of cervical cancer screening among urban and rural Nigerian women: a call for
389 education and mass screening. *Eur J Cancer Care (Engl)*. 2011 May;20(3):362–7.
- 390 17. McFarland DM. Cervical cancer and Pap smear screening in Botswana: knowledge and
391 perceptions. *Int Nurs Rev*. 2003 Sep;50(3):167–75.
- 392 18. Huchko MJ, Sneden J, Sawaya G, Smith-McCune K, Maloba M, Abdulrahim N, et al.
393 Accuracy of Visual Inspection with Acetic Acid to detect Cervical Cancer Precursors Among
394 HIV-infected Women in Kenya. *Int J Cancer J Int Cancer*. 2015 Jan 15;136(2):392–8.
- 395 19. Akinwuntan AL, Adesina OA, Okolo CA, Oluwasola OA, Oladokun A, Ifemeje AA, et al.
396 Correlation of cervical cytology and visual inspection with acetic acid in HIV-positive
397 women. *J Obstet Gynaecol J Inst Obstet Gynaecol*. 2008 Aug;28(6):638–41.
- 398 20. Singhakum N, Laiwejpithaya S, Chaopotong P. Digital Cervicography by Simply Portable
399 Device as an Alternative Test for Cervical Cancer Screening in Rural Area of Thailand.
400 *Asian Pac J Cancer Prev APJCP*. 2018;19(4):1145–9.
- 401 21. Khodakarami N, Farzaneh F, Aslani F, Alizadeh K. Comparison of Pap smear, visual
402 inspection with acetic acid, and digital cervicography as cervical screening strategies. *Arch
403 Gynecol Obstet*. 2011 Nov;284(5):1247–52.
- 404 22. Ricard-Gauthier D, Wisniak A, Catarino R, van Rossum AF, Meyer-Hamme U, Negulescu
405 R, et al. Use of Smartphones as Adjuvant Tools for Cervical Cancer Screening in Low-
406 Resource Settings. *J Low Genit Tract Dis*. 2015 Oct;19(4):295–300.

- 407 23. Weiser R, Morgado F, Dias P, Fernandes K, Levitz D. Approaches to blur reduction in
408 cervical images for automated visual evaluation. In: Optics and Biophotonics in Low-
409 Resource Settings IX [Internet]. SPIE; 2023 [cited 2024 Jun 14]. p. 7–11. Available from:
410 [https://www.spiedigitallibrary.org/conference-proceedings-of-](https://www.spiedigitallibrary.org/conference-proceedings-of-spie/PC12369/PC1236907/Approaches-to-blur-reduction-in-cervical-images-for-automated-visual/10.1117/12.2651693.full)
411 [spie/PC12369/PC1236907/Approaches-to-blur-reduction-in-cervical-images-for-automated-](https://www.spiedigitallibrary.org/conference-proceedings-of-spie/PC12369/PC1236907/Approaches-to-blur-reduction-in-cervical-images-for-automated-visual/10.1117/12.2651693.full)
412 [visual/10.1117/12.2651693.full](https://www.spiedigitallibrary.org/conference-proceedings-of-spie/PC12369/PC1236907/Approaches-to-blur-reduction-in-cervical-images-for-automated-visual/10.1117/12.2651693.full)
- 413 24. Bhanurangarao M, Mahaveerakannan R. Improving Skin Lesion Diagnosis: Hybrid Blur
414 Detection for Accurate Dermatological Image Analysis. In: Rajagopal S, Popat K, Meva D,
415 Bajaja S, editors. Advancements in Smart Computing and Information Security. Cham:
416 Springer Nature Switzerland; 2024. p. 225–40.
- 417 25. Ekem L, Skerrett E, Huchko MJ, Ramanujam N. Automated Image Clarity Detection for the
418 Improvement of Colposcopy Imaging with Multiple Devices [Internet]. Rochester, NY; 2024
419 [cited 2024 Jun 11]. Available from: <https://papers.ssrn.com/abstract=4725066>
- 420 26. Mccutcheon J. The vanishing author in computer-generated works: A critical analysis of
421 recent Australian case law. *Melb Univ Law Rev.* 2013 Jan 1;36:915–69.
- 422

Figure 1.



medRxiv preprint doi: <https://doi.org/10.1101/2024.11.05.24316753>; this version posted November 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 2.





Figure 3.



medRxiv preprint doi: <https://doi.org/10.1101/2024.11.05.24316753>; this version posted November 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 1.

	Pocket Arm (n = 196)	VIA Arm (n = 208)	Total (n = 404)
	N (%)	N (%)	N (%)
Age by category			
25-34	49 (25.0)	56 (26.9)	102 (25.2)
35-44	87 (44.4)	81 (35.2)	168 (41.6)
45-54	45 (23.0)	46 (21.1)	91 (22.5)
55-65	15 (7.7)	25 (10.1)	40 (9.9)
Clinic locations for screening			
Lumumba	68 (34.6)	70 (33.7)	138 (34.2)
Nyangande	27 (13.7)	28 (13.5)	55 (26.4)
Nyalenda	7 (3.6)	17 (8.2)	24 (5.9)
Rabuor	27 (13.7)	36 (17.3)	63 (15.6)

Hongo Ogosa	54 (27.6)	48 (23.1)	102 (25.2)
Gita	13 (6.6)	9 (4.3)	22 (5.4)

Parity

0	3 (1.5)	5 (2.4)	8 (2.0)
1	18 (9.2)	21 (10.1)	39 (9.7)
2	34 (17.3)	25 (12.0)	59 (14.6)
3	42 (21.4)	43 (20.7)	85 (21.0)
4	4 (20.4)	43 (20.7)	47 (11.6)
5 or more children	66 (33.7)	64 (30.8)	130 (32.2)
Answer not indicated	7 (3.6)	7 (3.4)	14 (3.5)

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.05.24316753>; this version posted November 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Prior cervical cancer screening

Yes	103 (52.6)	104 (50.0)	207 (51.2)
No	86 (43.9)	97 (46.6)	183 (45.3)
Answer not indicated	7 (3.6)	7 (3.4)	14 (3.5)

Screening result for those who indicated having prior cervical cancer screening (above, n = 207)

	Pocket Arm (n=103) N (%)	VIA Arm (n=104) N (%)	Total (n=207) N (%)
Positive	3 (2.9)	2 (1.9)	5 (2.4)
Negative	96 (93.2)	100 (96.2)	196 (94.7)
I don't know	4 (1.9)	2 (1.9)	6 (3.0)

Contraceptive use

Yes	69 (35.2)	90 (43.2)	159 (39.4)
No	120 (61.2)	110 (52.9)	230 (56.9)
Decline to answer	0 (0.0)	1 (0.5)	1 (0.2)
Answer not indicated	7 (3.6)	7 (3.4)	14 (3.5)

Type of contraceptives used for those who indicated using contraceptives (above, n = 159)

	Pocket Arm (n=69) N (%)	VIA Arm (n=84) N (%)	Total (n=159) N (%)
--	-------------------------------	----------------------------	---------------------------

Injectable	13 (18.8)	8 (8.9)	21 (13.2)
Pills	0 (0.0)	1 (1.1)	1 (0.6)
IUD	1 (1.4)	0 (0.0)	1 (0.6)
Female Sterilization	1 (1.4)	0 (0.0)	1 (0.6)
Implant	16 (23.2)	26 (28.9)	42 (26.4)
Male Condom	4 (5.8)	6 (6.7)	10 (11.1)
Other	0 (0.0)	0 (0.0)	0 (0.0)
Answer not indicated	34 (49.3)	49 (54.4)	83 (52.2)

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.05.24316210>; this version posted November 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 2.

	Pocket Arm (n = 191)		VIA Arm (n = 197)		Total (n = 388)
	N (%) Total patients	N (% of pathology category) Correct diagnosis	N (%) Total patients	N (% of pathology category) Correct diagnosis	N (%) Total patients in both arms
NILM	145 (75.9)	132 (91.0)	155 (80.2)	133 (85.8)	300 (77.3)
CIN1	8 (4.2)	4 (50.0)	14 (7.1)	9 (35.7)	22 (5.7)
CIN2	3 (1.6)	0 (0.0)	5 (2.5)	3 (60.0)	8 (2.1)
CIN3	33 (17.3)	10 (30.3)	19 (9.6)	3 (15.8)	52 (13.4)
CIN2/3	36 (18.8)	10 (27.8)	24 (12.2)	6 (25.0)	60 (15.5)
SCC	2 (1.0)	0 (0.0)	3 (1.5)	1 (33.3)	5 (1.3)
AGC	0 (0.0)	N/A	1 (0.5)	0 (0.0)	1 (0.3)

At the time of data analysis, 388 out of 404 enrolled patients had processed biopsy results. The remaining 16 were lost during processing resulting in a sample size of 191 and 197 for the Pocket arm and the VIA arm, respectively. The sample size in Tables 3, 4, and 5 are consistent with that in Table 2. NILM = negative for intraepithelial lesion or malignancy; CIN1, CIN2, CIN3 = cervical intraepithelial neoplasia grades 1-3; SCC = squamous cell carcinoma; AGC = atypical glandular cells

Table 3.

	Pocket Arm (n = 191)	VIA Arm (n = 197)
Sensitivity	26.3%	25.0%
Specificity	88.9%	84.0%
PPV	37.0%	20.6%
NPV	82.9%	87.1%

Positive pathology diagnosis = HSIL/CIN2, HSIL/CIN3, SCC, AGC
Negative pathology diagnosis = NILM, LSIL/CIN1

Table 4.

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.05.24316753>; this version posted November 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

	Pocket (n = 191) N (%)	VIA (n = 197) N (%)
8. Did any patient share their discomfort, concerns or pain during today's exam?		
Yes	53 (27.7)	53 (26.9)
No	138 (72.2)	144 (73.1)
10. Did you run into any of the following challenges during today's exam?		
No challenges	184 (96.3)	191 (97.0)
Difficulty with internet	1 (0.5)	N/A
Difficulty visualizing cervix	5 (2.6)	1 (0.5)
Difficulty recording patient info or results	1 (0.5)	0 (0)
Patient refusal	0 (0)	1 (0.5)
Patient discomfort	1 (0.5)	4 (2.0)

Table 5.

	Pocket (n = 190) N (%)	VIA (n = 197) N (%)
Did a provider explain why it is important to get treated for cervical cancer?		

	Pocket (n = 190)	VIA (n = 197)
	N (%)	N (%)
Yes	189 (99.5)	196 (99.5)
No	1 (0.5)	1 (0.5)

Did a provider explain why they did today's exam with either the Pocket or VIA?

Yes	189 (99.5)	197 (100.0)
No	1 (0.5)	0 (0.0)

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.05.24316753>; this version posted November 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).

Prior to today's visit, how much did you know about cervical cancer and cervical cancer prevention?

None	41 (21.6)	43 (21.8)
A little	139 (73.2)	146 (74.1)
Somewhat	10 (5.3)	6 (3.0)
Very much	0 (0)	2 (1.0)

After today's visit, how much do you know about cervical cancer and cervical cancer prevention?

None	1 (0.5)	1 (0.5)
A little	35 (18.4)	29 (14.7)
Somewhat	137 (72.1)	139 (70.6)
Very much	17 (8.9)	28 (14.2)

Did you experience any pain throughout your exam?

None	23 (12.1)	19 (9.6)
A little	154 (81.1)	164 (83.2)
Somewhat	13 (6.8)	14 (7.1)
Very much	0 (0)	0 (0)

How confident are you in the provider's assessment from today's visit?

None	0 (0.0)	0 (0.0)
------	---------	---------

	Pocket (n = 190)	VIA (n = 197)
	N (%)	N (%)
A little	6 (3.2)	5 (2.5)
Somewhat	54 (28.4)	56 (28.4)
Very much	130 (68.4)	136 (69.0)
Don't Know	0 (0.0)	0 (0.0)
How likely would you recommend this medical exam to a friend?		
Not likely at all	0 (0.0)	1 (0.5)
Not likely	2 (1.1)	0 (0.0)
Likely	43 (22.6)	37 (18.8)
Very likely	145 (76.3)	159 (80.7)

medRxiv preprint doi: <https://doi.org/10.1101/2024.11.05.24316753>; this version posted November 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

The participant survey was administered verbally directly following the exam with Pocket or VIA.



Figure 2

Histopathology:

NILM

CIN 1

CIN 2

CIN 3

Pre-Acetic
Acid
White-light
Capture



Acetic Acid
White-light
Capture



Acetic Acid
Green-light
Capture



Figure 3




Figure 1